Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil

This prospective, observational, open-label study aimed to provide access to ustekinumab prior to market authorization and assess its safety and effectiveness in patients with Crohn’s disease (CD) refractory to anti-tumor necrosis factor-α and conventional drugs in Brazil. Patients with a diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Chebli, Julio Maria Fonseca, Parra, Rogério Serafim, Flores, Cristina, Moraes, Antonio Carlos, Nones, Rodrigo Bremer, Gomes, Tarcia Nogueira Ferreira, Perdomo, Ana Maria Bravo, Scapini, Gustavo, Zaltman, Cyrla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654680/
https://www.ncbi.nlm.nih.gov/pubmed/36362709
http://dx.doi.org/10.3390/jcm11216481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654680/
https://www.ncbi.nlm.nih.gov/pubmed/36362709
http://dx.doi.org/10.3390/jcm11216481

Ejemplares similares